– May 1, 2005
May 1, 2005
View Archives Issues
-
C-Reactive Protein: A Marker for Aggressive Hepatocellular Carcinoma
C-reactive protein (CRP) is an acute phase reactant that is synthesized by hepatocytes in response to inflammatory signals. Hashimoto and colleagues at Fukuoka City Hospital in Japan performed a retrospective analysis of 141 patients who underwent curative resection for hepatocellular carcinoma (HCC). -
Late Second Malignancies in Lymphoma Marrow Transplant Survivors
Myelodysplasia (MDS) and acute Myelogenous Leukemia (AML) are known to occur in a fraction of patients following autologous bone marrow transplantation (ABMT), but the development of solid tumors in this setting has not been fully characterized. -
Chemotherapy Permits Resection of Metastatic Colorectal Cancer: Experience from Intergroup N9741
Colorectal cancer is the second leading cause of cancer death worldwide. Fifteen to 25% of patients will present with metastatic disease. Approximately, half of them will develop liver metastases at some point during the course of the disease. -
Gemcitabine Schedules for Poor Performance Status Lung Cancer Patients
Advanced lung cancer frequently occurs in patients who have comorbid illness and poor performance status. Baka and colleagues from Manchester, United Kingdom, performed a phase II study comparing 2 different schedules of gemcitabine in patients with impaired physical performance as reflected by a Karnofsky performance status (KP) of ≤ 70. -
Effects of Long-Term Vitamin E Supplementation on Cardiovascular Events and Cancer
The rationale for this study is interesting. as the trial investigators point out, oxidative injury has been implicated as a key mechanism, leading to atherosclerotic cardiovascular disease and cancer. -
High Tech Prognostication for Ovarian Cancer Patients
Given the widely variant survival characteristics of women with advanced ovarian cancer, discrete quantifiable differences in tumor biology must exist. Heretofore, accurate characterization has been elusive. -
Pharmacology Watch: The FDA Pulls Another COX-2 Inhibitor Off the Market
-
Clinical Briefs in Primary Care supplement